• News
  • Health

AnaptysBio reports success in development of new antibody

AnaptysBio Inc., a privately-held therapeutic antibody developer, is reporting the development of a new therapeutic antibody to interleukin-33, a pro-inflammatory cytokine associated with tissue damage and increased incidence of atopic dermatitis and severe asthma.

To continue reading, subscribe now
log in to your account
User Response
0 UserComments
Subscribe Today!